Development of a contemporary bleeding risk model for elderly warfarin recipients

Chest

Volumn 130, Issue 5, 2006, Pages 1390-1396

  Shireman, Theresa I ^a   Mahnken, Jonathan D ^a   Howard, Patricia A ^a   Kresowik, Timothy F ^b   Hou, Qingjiang ^a   Ellerbeck, Edward F ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Adverse effects; Anticoagulants; Atrial fibrillation; Complications; Drug therapy; Epidemiology; Hemorrhage; Risk; Therapeutic use; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TICLOPIDINE; WARFARIN;

AGED; ALCOHOL ABUSE; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PRACTICE; COHORT ANALYSIS; DIABETES MELLITUS; DRUG ABUSE; ELDERLY CARE; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MODEL; PRIORITY JOURNAL; RISK ASSESSMENT; VALIDATION PROCESS;

EID: 33751255101     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.5.1390     Document Type: Article

References (40)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-1457
2. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97:1231-1233
3. Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31:822-827
4. Jencks SF, Guerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. JAMA 2000; 284:1670-1676
5. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. JAMA 2003; 289:305-312
6. McCrory DC, Matchar DB, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155:277-281
7. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87:144-152
8. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105:91-99
9. Wells PS, Forgie MA, Simms M, et al. The Outpatient Bleeding Risk Index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 2003; 163:917-920
10. Aspinall SL, DeSanzo BE, Trilli LE, et al. Bleeding risk index in an anticoagulation clinic: assessment by indication and implications for care. J Gen Intern Med 2005; 20:1008-1013
11. Kuijer PMM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism Arch Intern Med 1999; 159:457-460
12. Howard PA, Ellerbeck EF, Engelman KK, et al. Warfarin for stroke prevention in octogenarians with atrial fibrillation. Am J Geriatr Cardiol 2001; 10:139-144
13. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993; 153:1557-1562
14. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897-902
15. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. Ann Intern Med 1993; 118:511-520
16. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156:409-416
17. Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124:970-979
18. Wehinger C, Stollberger C, Langer T, et al. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke 2001; 32:2246-2252
19. Pengo V, Legnani C, Noventa F, et al. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding: a multicenter inception cohort study. Thromb Haemost 2001; 85:418-422
20. Howard PA, Dunn MI. Update on drug interactions: warfarin and anti-infective agents. J Respir Dis 1998; 19:1037-1046
21. Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf 1994; 10:381-394
22. Howard PA, Ellerbeck EF, Engelman KK, et al. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002; 11:569-576
23. Quilliam BJ, Lapane KL, Eaton CB, et al. Effects of antiplatelet and anticoagulant agents on risk of hospitalization for bleeding among a population of elderly nursing home stroke survivors. Stroke 2001; 32:2299-2304
24. Shireman TI, Howard PA, Kresowik TF, et al. Combined anticoagulant- antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35:2362-2367
25. Fisher ES, Wennberg JE, Stukel TA, et al. Hospital readmission rates for cohorts of Medicare beneficiaries in Boston and New Haven. N Engl J Med 1994; 331:989-995
26. Tirschwell DL, Longstreth WT. Validating administrative data in stroke research. Stroke 2002; 33:2465-2470
27. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York, NY: John Wiley & Sons, 2000
28. Rao PV. Statistical research methods in the life sciences. Pacific Grove, CA: Brooks/Cole Publishing Company, 1998
29. SAS Institute Inc. SAS/STAT 9.1 user's guide. Cary, NC: SAS Institute Inc, 2004
30. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York, NY: Springer-Verlag New York, 1997
31. Gasse C, Hollowell J, Meier CR, et al. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005; 94:537-543
32. Lip GY, Varughese GL. Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int J Cardiol 2005; 105:319-321
33. Ostgren CJ, Merlo J, Rastam L, et al. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004; 6:367-374
34. DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149:650-656
35. McMahan DA, Smith DM, Carey MA, et al. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998; 13:311-316
36. White RH, Beyth RJ, Zhou H, et al. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999; 107:414-424
37. Steffensen FH, Kristensen K, Ejlersen E, et al. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997; 242:497-503
38. Matchar DB, Samsa GP. Secondary and tertiary prevention of stroke: patient outcomes research team; excerpts, seventh progress report. Durham, NC: Center for Health Policy Research and Education, Duke University, 1995
39. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119(suppl):194S-206S
40. Lip GYH, Zarifis J, Watson RDS, et al. Physician variation in the management of patients with atrial fibrillation. Heart 1996; 75:200-205